Intro

The hosts explore the FLOW trial's findings on the renal outcomes of a medication for patients with type 2 diabetes and obesity, emphasizing the increased risks of kidney and heart disease in these populations. They stress the importance of focusing on heart and kidney health in managing complications and using kidney protective medications to prevent adverse events in diabetic patients.